Advertisement

Pharmaceutisch Weekblad

, Volume 8, Issue 4, pp 229–233 | Cite as

Specimen handling in an HPLC determination of phenylbutazone and its major metabolites in plasma, avoiding degradation of the compounds

  • M. J. A. M. Franssen
  • Y. Tan
  • I. Freij
  • C. A. M. Van Ginneken
  • F. W. J. Gribnau
Original Articles

Abstract

A problem usually not taken into account when a quantitative HPLC method for phenylbutazone is developed is the degradation of this drug and its metabolites not only upon storage, but also on extraction under acidic conditions, especially when the temperature is raised. Moreover, the degradation products in the chromatograms may interfere with the determination of gammahydroxyphenylbutazone. In our newly developed HPLC method, using feprazone as an internal standard, extreme care is taken to avoid degradation of the compounds during the extraction procedure. In view of the present results it is concluded that previously published data on phenylbutazone, oxyphenbutazone and gammahydroxyphenylbutazone levels should be considered with reserve.

Key words

Analysis, quantitative Chromatography, high pressure liquid Gammahydroxyphenylbutazone Oxyphenbutazone Phenylbutazone Stability 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Inham WH. Study of fatal bone marrow depression with special reference to phenylbutazone and oxyphenbutazone. Br Med J 1977;1:1500–5.PubMedGoogle Scholar
  2. 2.
    Burns JJ, Rose RK, Chenkin T, Goldman A, Schülert A, Brodie BB. The physiological disposition of phenylbutazone (Butazolidine®) in man and a method for its estimation in biological material. J Pharmacol Exp Ther 1953;109:346–57.PubMedGoogle Scholar
  3. 3.
    Burns JJ, Rose RK, Goodwin S, Reickenthal J, Horning EC, Brodie BB. The metabolic fate of phenylbutazone in man. J Pharmacol Exp Ther 1955;113:481–9.PubMedGoogle Scholar
  4. 4.
    Wallace JE. Ultraviolet spectrophotometric determination of phenylbutazone in biologic specimens. J Pharm Sci 1968;57:2053–6.PubMedGoogle Scholar
  5. 5.
    Perego R, Martinelli E, Vanoni PC. Gas chromatographic assay of phenylbutazone in biological fluids. J Chromatogr 1971;54:280–1.CrossRefPubMedGoogle Scholar
  6. 6.
    McGilveray IJ, Midha KK, Brien R, Wilson R. The assay of phenylbutazone in human plasma by specific and sensitive gas-liquid chromatographic procedure. J Chromatogr 1974;89:17–22.CrossRefPubMedGoogle Scholar
  7. 7.
    Bruce RB, Maynard WR, Dunning LK. Oxyphenbutazone and phenylbutazone determination in plasma and urine by GLC. J Pharm Sci 1974;63:446–8.PubMedGoogle Scholar
  8. 8.
    Midha KK, McGilveray IJ, Charette C. GLC determination of plasma concentration of phenylbutazorle and its metabolite oxyphenbutazone. J Pharm Sci 1974;63:1234–9.PubMedGoogle Scholar
  9. 9.
    Midha KK, McGilveray IJ, Charette C. GLC determination of gammahydroxyphenylbutazone in plasma. J Pharm Sci 1974;63:1751–4.PubMedGoogle Scholar
  10. 10.
    Sioufi A, Candal F, Marfil F. GLC determination of phenylbutazone in human plasma. J Pharm Sci 1978;67:243–5.PubMedGoogle Scholar
  11. 11.
    Budd RD. Gas chromatographic determination of phenylbutazone in biological fluids. J Chromatogr 1982;243:368–71.CrossRefPubMedGoogle Scholar
  12. 12.
    Pound NJ, McGilveray IJ, Sears RW. Analysis of phenylbutazone in plasma by high-speed liquid chromatograpy. J Chromatogr 1974;89:23–30.CrossRefPubMedGoogle Scholar
  13. 13.
    Pound NJ, Sears RW. Simultaneous determination of phenylbutazone and oxyphenbutazone in plasma by high-speed liquid chromatography. J Pharm Sci 1975;64:284–7.PubMedGoogle Scholar
  14. 14.
    Alvinerie M. Reversed phase high-performance liquid chromatography of phenylbutazone in body fluids. J Chromatogr 1980;181:132–4.PubMedGoogle Scholar
  15. 15.
    Aarons L, Higham C. An improved HPLC assay for monitoring phenylbutazone and its two major oxidised metabolites in plasma. Clin Chim Acta 1980;105:377–82.CrossRefPubMedGoogle Scholar
  16. 16.
    Marunaka T, Shibata T, Minami Y, Umeno Y. Simultaneous determination of phenylbutazone and its metabolites in plasma and urine by high-performance liquid chromatography. J Chromatogr 1980;183:331–8.PubMedGoogle Scholar
  17. 17.
    Bellward GD, Morgan RG, Beauline VH, Mitchell AG. Effect of phenylbutazone breakdown produced on drug metabolism assay. J Pharm Pharmacol 1972;24:338–9.PubMedGoogle Scholar
  18. 18.
    Awang DVC, Vincent A, Matsui F. Pattern of phenylbutazone degradation. J Pharm Sci 1973;62:1673–6.PubMedGoogle Scholar
  19. 19.
    Matsui F, Robertson DL, Poirier MA, Lovering EG. Identification of degradation products in a phenylbutazone tablet formulation. J Pharm Sci 1980;69:469–71.PubMedGoogle Scholar
  20. 20.
    Fabre H, Mandron B, Eddine H. Quality control of phenylbutazone. II: analysis of phenylbutazone and its decomposition products in drugs by high-pressure liquid chromatography. J Pharm Sci 1982;71:120–2.PubMedGoogle Scholar
  21. 21.
    Aarbakke J, Bakke OM, Milde ET, Davies DS. Disposition and oxidative metabolism of phenylbutazone in man. Eur J Clin Pharmacol 1977;11:359–66.CrossRefPubMedGoogle Scholar
  22. 22.
    Dieterle W, Faigle JW, Früh F, et al. Metabolism of phenylbutazone in man. Drug Res 1976;26:572–7.Google Scholar

Copyright information

© Bohn, Scheltema & Holkema 1986

Authors and Affiliations

  • M. J. A. M. Franssen
    • 1
    • 2
  • Y. Tan
    • 1
  • I. Freij
    • 1
  • C. A. M. Van Ginneken
    • 1
  • F. W. J. Gribnau
    • 1
  1. 1.Division of Clinical Pharmacology and Pharmacokinetics, Institute of PharmacologySt. Radboud HospitalHB NijmegenThe Netherlands
  2. 2.Division of Rheumatology, Department of Internal MedicineSt. Radboud HospitalHB NijmegenThe Netherlands

Personalised recommendations